Is that the reason why Cellectar Biosciences, Inc. (CLRB), stock muddled in the post market hours Tuesday?

Cellectar Biosciences, Inc. (NASDAQ:CLRB), shares were dipping -22.38% to $2.15 in the ‎after-hours session on Tuesday after the company, focused on the discovery, development ‎and commercialization of new cancer therapies, Cellectar Biosciencesannounced that it ‎plans to offer and sell shares of its common stock and its common stock equivalents in a ‎public offering. There is no guarantee as to whether the offering will be completed, or as to ‎the size or terms of the offering, since it is subject to market conditions.‎

Get the hottest stocks to trade every day before the market ‎opens 100% ‎free. Click here now. 

‎Upon completion of the public offering, the Company expects to sell shares of common ‎stock and convertible preferred stock at the public offering price to certain investors in a ‎private placement.‎

Read More

Oppenheimer & Co. Inc. is acting solely as an underwriter in the public offering.‎‎

Get the hottest stocks to trade every day before the ‎market opens 100% ‎free. Click here now. 

‎Under the shelf ‎registration statement previously filed with, and declared effective by, the Securities and ‎Exchange Commission (SEC) on August 20, 2020, Cellectar will issue shares of common stock ‎and common stock equivalents in the public offering. Only the prospectus and it’s ‎supplement will be distributed in connection with this offering. With the Securities and ‎Exchange Commission (SEC), the Company will file an initial prospectus supplement and an ‎accompanying prospectus relating to the public offering. Additional copies of the ‎preliminary prospectus supplement and accompanying prospectus may be obtained by ‎contacting Oppenheimer & Co. Inc. at 85 Broad Street, 26th Floor, New York, NY, 10004, or ‎by emailing‎

Related posts